Recbio Technology
02179.HKTaizhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileOverview
A Chinese vaccine innovator with proprietary adjuvant and protein engineering platforms, advancing late-stage HPV and shingles vaccines.
Infectious Disease
Technology Platform
An integrated vaccine innovation engine consisting of a proprietary novel adjuvant platform for enhancing immune responses, a protein engineering platform for antigen design, and an immunological evaluation platform.
Opportunities
Large addressable markets in China for HPV and shingles vaccines, with potential for international expansion facilitated by EU GMP-certified manufacturing and proprietary adjuvant technology.
Risk Factors
Clinical and regulatory risks for late-stage candidates, intense competition in the HPV vaccine space from established players, and execution risk in scaling manufacturing and commercialization.
Competitive Landscape
Faces competition in HPV from Merck's Gardasil 9 and domestic players like Walvax, and in shingles from GSK's Shingrix; differentiation stems from in-house novel adjuvant development and integrated platform.